Introduction
============

Changes in myelin- and oligodendrocyte-related genes have been implicated in the pathophysiology of schizophrenia. Postmortem studies of multiple brain regions show dysregulation of myelin-associated genes in schizophrenia (Fannon et al., [@B11]; Hakak et al., [@B14]; Aston et al., [@B2]; Katsel et al., [@B19]; Haroutunian et al., [@B15]) and of these, the myelin-associated glycoprotein (*MAG*) gene is consistently among the most down-regulated. Additionally, two candidate gene studies have found associations of *MAG* variants with schizophrenia: Yang et al. ([@B41]), in a transmission disequilibrium test (TDT) analysis of 413 Chinese Han trios, found positive associations with two-marker haplotypes of rs720308 and rs720309, and Wan et al. ([@B40]), using a case--control design (*n*~case~ = 470, *n*~control~ = 470, also Chinese Han), found the same markers significantly associated with schizophrenia. More recently, we found a significant association between *MAG* genotype at these same loci and total cortical gray matter volume in first episode schizophrenia patients (Voineskos et al., [@B39]), however, no study has yet examined the regional effects of these SNPs on the brain.

Brain matter abnormalities in the frontal and temporal cortices are among the most common findings in neuroimaging studies of schizophrenia (Fornito et al., [@B13]; Shenton et al., [@B29]). Structural analyses of brain changes in schizophrenia have principally found volume deficits in the superior temporal gyrus as well as medial temporal lobe structures, such as the hippocampus and parahippocampal gyrus (Shenton et al., [@B29]). Abnormalities of the prefrontal cortex have also been identified in schizophrenia (Shenton et al., [@B29]). Disruptions of the parietal and occipital lobes, though less studied than other brain regions in schizophrenia, may also be features of this disease. Schlaepfer et al. ([@B27]) and Ross and Pearlson ([@B26]) have demonstrated reductions in gray matter of the heteromodal association cortex, which includes the inferior parietal lobule, in schizophrenia patients.

Biologically convergent lines of evidence have independently implicated *MAG* locus variation and cortical gray matter volume deficits as potential schizophrenia liability factors. The present study builds on our previous association of *MAG* with total cortical gray matter volume in schizophrenia by analyzing the effect of *MAG* genotype on regional cortical brain gray and white matter volumes. We also examined effects of genotype on the hippocampus since there is evidence for altered *MAG* regulation in schizophrenia in this region (Dracheva et al., [@B10]). We hypothesized, based on postmortem data and our previous work, that *MAG* genotype would predict variation in cortical gray matter volumes, particularly in frontal and temporal brain regions. Furthermore, given altered expression of the *MAG* gene in schizophrenia, as well as our previous findings of reduced cortical gray mater in schizophrenia patients only, we hypothesized that there may be a genotype by diagnosis interaction predicting variation in brain imaging measures.

Materials and Methods
=====================

Sample selection
----------------

Study participants were recruited at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada by referral, study registries, and advertisements. To characterize clinical symptoms, participants were administered the structured clinical interview for DSM-IV disorders (SCID; First et al., [@B12]) and the positive and negative syndrome scale (PANSS), and were interviewed by a psychiatrist at CAMH to ensure diagnostic accuracy. Details on history of medication were gathered by self-report and verified when necessary by the treating psychiatrist and chart review. All participants were Caucasian and between 18 and 59 years of age. Exclusion criteria for patients included any history of substance dependence or abuse within the past 6 months, previous head trauma, loss of consciousness, and neurological disorders. For controls, additional exclusion criteria included any history of a primary psychotic disorder in first-degree relatives. Controls were group matched to patients based on age, gender, and handedness (Edinburgh handedness inventory; Oldfield, [@B23]). Written and informed consent was obtained and the study was approved by the CAMH Ethics Review Board.

Genotyping
----------

Subjects were genotyped for two SNPs at the *MAG* locus (rs720308 and rs720309). DNA was extracted from blood samples using a modified high-salt method (Lahiri and Nurnberger, [@B20]), and checked for concentration using the NanoDrop 8000 spectrophotometer. Samples were deemed acceptable if their concentration was \>0.02 μg/μl and optical density (OD) A260/280 ratio between 1.5 and 2.5. Samples were then diluted to a final concentration of 20 ng/μl for genotype analysis. Genotyping was done using the Taqman Assay-on-Demand protocol with a total PCR reaction volume of 10 μl. Markers were analyzed post-amplification using the Applied Biosystems 7500 Real-Time PCR System for allelic discrimination, and calls were made manually. Two lab personnel independently verified results and 10% of sample genotypes were duplicated for quality control.

Image acquisition
-----------------

High resolution magnetic resonance images were acquired as part of a multi-modal imaging protocol using an eight-channel head coil on a 1.5-T GE Echospeed system (General Electric Medical Systems, Milwaukee, WI, USA), which permits maximum gradient amplitudes of 40 mT/m. Axial inversion recovery prepared spoiled gradient recall images were acquired: echo time (TE) = 5.3 ms, repetition time (TR) = 12.3 ms, time to inversion (TI) = 300 ms, flip angle = 20°, number of excitations (NEX) = 1 (124 contiguous images, 1.5 mm thickness).

Image processing
----------------

For cortical volume analysis, each subject's T1 image was submitted to the CIVET pipeline (version 1.1.7 developed at the Montreal Neurologic Institute; Ad-Dab'bagh et al., [@B1]). The processing steps included registration to the symmetric ICBM 152 template (Mazziotta et al., [@B21]) with a 12-parameter linear transformation (Collins, [@B6]), correction for inhomogeneity artifact (Sled et al., [@B30]), skull stripping (Smith et al., [@B33]), tissue classification into white and gray matter, cerebrospinal fluid and background (Zijdenbos et al., [@B43]; Tohka et al., [@B36]), and neuroanatomical segmentation using ANIMAL (Collins et al., [@B7]). Total volumes for each cortical lobe were estimated for each individual by non-linearly warping each T1 image toward a segmented atlas. Volume (mm^3^) was extracted from each of these regions using the RMINC package (version 0.4) for reading and analyzing MINC2 output files. Total gray matter, white matter, and CSF volumes were calculated, along with lobar cortical gray and white matter volumes (i.e., left and right frontal, temporal, parietal, occipital).

For hippocampal volumes, each individual's T1-weighted image was processed using the FMRIB's Integrated Registration and Segmentation Tool (FIRST v1.2) automated subcortical segmentation pipeline (Patenaude, [@B24]; Patenaude et al., [@B25]) included in the open access FSL (v.4.1.8) package. This method uses a Bayesian modeling framework based on multivariate Gaussian assumptions to estimate the shape and appearance of subcortical structures. To achieve this, it employs point distribution and surface mesh models generated from a set of 336 manually segmented images (provided by the Centre for Morphometric Analysis (CMA), MGH, Boston). Each subject's image was registered using FLIRT (Jenkinson et al., [@B17]) in a two-step transformation (each step using 12 degrees of freedom) that first affine-registered whole-head images to non-linear MNI152 space (1 mm resolution) and then excluded voxels outside a subcortical mask (generated from the filled average shapes of all subcortical structures being segmented in the MNI space). The automated segmentation process then computed the most probable shape of each structure by comparing linear combinations of shape principal components from the manually segmented models to the observed intensities from each input image. The resulting vertex models were then transformed back to native space, boundaries corrected, and volumes were calculated for left and right hippocampus.

Brain tissue volume, normalized for subject head size, was estimated with SIENAX (Smith et al., [@B32]; Smith, [@B31]), also part of the FSL toolkit. First, brain and skull images were extracted from the single whole-head images (Smith, [@B31]) and then affine-registered to MNI152 space (Jenkinson and Smith, [@B18]) (using the skull image to determine registration scaling). Next, tissue-type segmentation with partial volume estimation was carried out (Zhang et al., [@B42]) in order to calculate total volume of brain tissue (including separate volume estimates of gray matter, white matter, peripheral gray matter, and ventricular CSF).

Statistical analysis
--------------------

Statistical packages for the social sciences (SPSS) version 19 was used for statistical analysis. Individuals were grouped by genotype at rs720308 and rs720309 as either major allele (A/T) homozygotes or minor allele (G/A) carriers and a repeated measures general linear model (GLM) was applied. Separate analyses were carried out for lobar gray and white matter measures. For each cortical analysis, genotype and diagnosis were between-group factors, and eight within-group factors corresponding to left and right frontal, temporal, parietal, and occipital lobe volumes were used, with age and total brain volume as covariates. For hippocampal volume, a separate repeated measures analysis with two within-group factors (left and right hippocampus) was applied to determine effects of diagnosis and genotype, with total brain volume and age as covariates. Where repeated measures analyses showed significant associations, *post hoc* univariate GLM analysis was used to localize effects of genotype and/or diagnosis on brain morphometry measures.

Results
=======

A 100% successful genotyping rate was achieved. *MAG* genotype distribution was not significantly different between schizophrenia patients and controls and did not violate Hardy--Weinberg equilibrium (*p* = 0.578). The SNPs under investigation were in full linkage disequilibrium (*D*′ = 1) in this sample. Therefore, we proceeded with imaging--genetics analysis using only one of the two SNPs (we chose rs720308). There were no significant differences in gender (*p* = 0.503), age (*p* = 0.137), or ethnicity (all Caucasian) between the group of schizophrenia patients (*n* = 45) and controls (*n* = 47; Table [1](#T1){ref-type="table"}).

###### 

**Sample demographics information including *p*-value of group difference between controls and schizophrenics**.

  Demographic                          Controls (*n* = 47), mean (SD)   Schizophrenics (*n* = 45), mean (SD)   Difference (*p*)
  ------------------------------------ -------------------------------- -------------------------------------- ------------------
  Age                                  38(13)                           42(14)                                 0.137
  Education                            16(2)                            13(3)                                  \<0.001
  WTAR (IQ)                            118(8)                           110(16)                                0.002
  MMSE                                 29(1)                            29(1)                                  0.144
  CIRS-G                               0.6(0.6)                         2(0.6)                                 \<0.001
  Chlorpromazine equivalent (mg/day)   NA                               361(318)                               NA
  PANSS                                                                                                        
      Positive                         NA                               14(5)                                  NA
      Negative                         NA                               15(6)                                  NA
      General                          NA                               26(7)                                  NA
      Total                            NA                               55(16)                                 NA
  Gender                               13 F, 34 M                       16 F, 29 M                             0.503
  Antipsychotic treatment              NA                               2 1°, 35 2°, 2, none, 6 NA             

*Age, Education, WTAR, MMSE, and CIRS-G differences were assessed using independent sample *t*-tests, and Gender differences were assessed using Fisher's exact test*.

*NA, not applicable; M, male; F, female; WTAR, Wechsler Test for Adult Reading; MMSE, Mini Mental State Examination; CIRS-G, Clinical Information Rating Scale, Geriatrics*.

Repeated measures GLM found a significant region by genotype interaction (*F*~7,602~ = 2.8, *p* = 0.007, Greenhouse--Geisser correction: *F*~4,317~ = 2.8, *p* = 0.031) and significant region by genotype by diagnosis interaction (*F*~7,602~ = 3.2, *p* = 0.003, Greenhouse--Geisser correction: *F*~4,317~ = 3.2, *p* = 0.016) for lobar gray matter volumes. No significant associations were found with lobar white matter volumes (Genotype by region: *F*~7,602~ = 0.45, *p* = 0.87; genotype by region by diagnosis: *F*~7,602~ = 1.6, *p* = 0.12) or hippocampal volumes (Genotype by region: *F*~1,86~ = 0.21, *p* = 0.65; genotype by region by diagnosis: *F*~1,86~ = 2.43, *p* = 0.12).

Follow-up univariate GLM on bilateral lobar gray matter volumes found a main effect of diagnosis for frontal lobe volume (*F*~5,86~ = 5.361, *p* = 0.023), a main effect of genotype for temporal lobe volume (*F*~5,86~ = 7.318, *p* = 0.008), and a significant genotype by diagnosis interaction for parietal lobe volume (*F*~5,86~ = 6.478, *p* = 0.0127). However, after Bonferroni correction for four comparisons (*p* = 0.0125), only the temporal lobe finding remains significant, with the parietal lobe bordering on significance.

Further investigation of left and right hemispheres localized the temporal and parietal findings to the left side (*F* = 7.742, *p* = 0.007 and *F* = 7.930, *p* = 0.006, respectively), with analyses of the right temporal and parietal lobes failing to survive correction for multiple comparisons (*F* = 4.852, *p* = 0.03 and *F* = 3.245, *p* = 0.075, respectively). The AA genotype predisposed both schizophrenia patients and healthy controls to lower left temporal gray matter volume (Figure [1](#F1){ref-type="fig"}). In addition, this genotype predisposed schizophrenia patients to lower left parietal gray matter volume (Figure [2](#F2){ref-type="fig"}). Chlorpromazine (CPZ) equivalents of medication exposure (mg/day) were calculated for the schizophrenia patients (mean = 361, SD = 318) and regressed against lobar volumetric measures. No significant correlation of CPZ equivalents was found with any lobar brain measure.

![**Estimated marginal means of gray matter volume in the temporal lobe, by diagnosis and genotype at *MAG* rs720308, adjusted for age and total brain volume**. Genotype effect (*F* = 7.742, *p* = 0.007) is shown for left hemisphere. (HC, healthy controls, SCZ, schizophrenic patients).](fpsyt-03-00040-g001){#F1}

![**Estimated marginal means of gray matter volume in the parietal lobe, by diagnosis and genotype at *MAG* rs720308, adjusted for age and total brain volume**. Genotype by diagnosis interaction (*F* = 7.930, *p* = 0.006) is shown for left hemisphere. (HC, healthy controls, SCZ, schizophrenic patients).](fpsyt-03-00040-g002){#F2}

Discussion
==========

The present study used a carefully matched sample of schizophrenia patients and healthy controls to examine the effects of putative *MAG* gene risk variants on brain morphometry. Our main findings were that variation in the *MAG* gene influenced temporal lobe gray matter volume in both schizophrenia patients and healthy controls, and left parietal lobe gray matter volume in schizophrenia patients. Our findings localize previously shown effects of the *MAG* gene on cortical gray matter to temporal and parietal regions. No association of this locus with white matter volumes or hippocampus was found.

Myelin system genes may play a key role in cortical brain growth, development, and maintenance, as these genes are critical in oligodendrocyte growth, maintenance, and repair during the adult lifespan. The *MAG* gene specifically supports axon stability and impulse transmission through its maintenance of the intermembrane distance of the periaxonal space (Nguyen et al., [@B22]). Considerable evidence points to abnormalities in expression of the *MAG* gene in the temporal lobe in schizophrenia (Hakak et al., [@B14]; Katsel et al., [@B19]; Haroutunian et al., [@B15]), aligning with temporal lobe volume reductions in this disorder. Furthermore, temporal lobe volume deficits in the left hemisphere are reported more frequently than those in the right (Sun et al., [@B35]). Our finding of *MAG* gene variation influence on left temporal lobe volume in healthy controls may represent an intermediate risk phenotype for schizophrenia. In schizophrenia patients, it is possible that the *MAG* rs720308 AA genotype could predict risk for poorer outcome or decreased cognitive reserve based on its effects on left temporal lobe volume. At the same time, effects of the *MAG* gene on left temporal volume may help explain heterogeneity of findings in neuroimaging studies of the temporal lobe in schizophrenia.

We found that *MAG* genotype interacted with diagnosis to predict gray matter volume in the parietal lobe. Dysfunction of the parietal lobe may play a critical role in schizophrenia pathophysiology, as it is a key functional domain for many cognitive processes commonly affected in schizophrenia (Torrey, [@B37]). Compared to the temporal lobe, far fewer reports of parietal lobe volume postmortem or *in vivo* with MRI have been published in schizophrenia. Those examining parietal tissue have focused on Brodmann area 7 and found dysregulation of several genes involved in apoptotic pathways and nerve maturation, but not of *MAG* itself (Katsel et al., [@B19]; Haroutunian et al., [@B15]). Nevertheless, our finding here provides an intriguing potential role for *MAG* gene variation in parietal lobe volume in schizophrenia. Similar to the heterogeneity in temporal lobe findings, *MAG* gene variation may provide one explanation for heterogeneity of parietal lobe findings in schizophrenia. A challenge in studying the parietal lobe is its anatomical variability, making it a difficult region to parcellate effectively. Furthermore, the histological division of inferior parietal structures, namely the angular and supramarginal gyri (Brodmann areas 39 and 40, respectively), has been reevaluated and seven distinct cytoarchitectonic areas identified using an observer-independent method (Caspers et al., [@B5]). With the advent of superior neuroanatomical parcelation methods in neuroimaging, future work might be able to examine the influence of *MAG* genotype in these more specialized regions.

Several potential biological mechanisms may explain the observed effects of *MAG* gene variation on brain morphology. First, variation in the *MAG* gene could potentially be responsible for the lower levels of MAG observed in postmortem schizophrenia brain. Second, regional differences of *MAG* expression may be responsible for myelin abnormalities that have been implicated in a number of demyelinating diseases bearing symptomatic congruency to schizophrenia (Davis et al., [@B8]). Myelin abnormalities have also been shown to result in axonal degeneration and a reduction in connectivity (Stewart and Davis, [@B34]), key elements of the myelin--oligodendrocyte hypothesis of schizophrenia pathology. Third, the effects of *MAG* on gray matter may occur indirectly. The *MAG* knockout mouse shows reduced density of pyramidal cell basal dendrites of the prefrontal cortex (Segal et al., [@B28]). Lack of MAG expression, and subsequent effects on other myelin system genes, could affect the ability of satellite oligodendrocytes (in gray matter) to support surrounding neurons (Baumann and Pham-Dinh, [@B3]). Finally, genetic variation in *MAG* may influence axonal organization and sprouting since MAG acts as part of a myelin-mediated complex that functions to inhibit axonal growth (Voineskos, [@B38]). This complex consists of several proteins encoded for by myelin related genes, including the *MAG* gene, the myelin--oligodendrocyte glycoprotein (*MOG*) gene, and the receptor tyrosine kinase erbB3 (*ErbB3*) gene, which bind to the Nogo-66 receptor (gene located in the 22q11 chromosomal region; Budel et al., [@B4]). Recent data supports that this complex may play a role in the etiopathogenesis of schizophrenia (Budel et al., [@B4]).

The *MAG* gene transcript is known to undergo alternative splicing and it is possible that the intronic SNPs investigated here may play a role in this process, though molecular studies will be needed to identify the functional effect of variation at these loci. An exploratory *in silico* analysis \[using the online TFSEARCH search tool (Akiyama; Heinemeyer et al., [@B16])\] of potential transcription factor (TF) binding sites at these loci has found a decrease in binding potential of the sex-determining region Y (*SRY*) protein predicted by the rs720309 T allele (corresponding to the rs720308 A allele). Interestingly, this male-specific TF is highly expressed in the brain and involved in the biochemical regulation of dopaminergic neurons of the nigrostriatal system (Dewing et al., [@B9]). Although this raises the possibility of sex interactions, we have an insufficient sample size to test such a hypothesis here. Additionally, it should be noted that these SNPs are not near the promoter region of the *MAG* gene -- leaving the possibility of distal enhancer effects of this TF on MAG expression.

There are several limitations that should be considered in this study. First, as in any structural neuroimaging investigation, partial volume effects can lead to misclassification of tissue. Second, while it is possible that our association is a false positive result, the fact that the present finding is in the same direction as our previous *MAG* imaging--genetics result on total cortical gray matter volume reduces this concern. Third, newer imaging techniques for evaluating white matter may reveal associations with *MAG* gene variants. We are addressing this as part of our ongoing studies. Finally, medication effects on brain volumes cannot be ruled out, despite the fact that no relationship with chlorpromazine equivalent dose was found. Our previous finding of association of this variant with cortical gray matter volume in a largely unmedicated, first episode schizophrenia sample (Voineskos et al., [@B39]) should also help alleviate concerns regarding this potential confound.

In conclusion, we have identified that variation in the *MAG* gene influences temporal gray matter volumes in healthy controls and chronic schizophrenia patients, and parietal gray matter volumes in schizophrenia patients only. Our findings highlight a potential risk mechanism for temporal lobe volume reduction in schizophrenia via variation at the *MAG* gene, and that heterogeneity in structural neuroimaging findings in schizophrenia may be in part due to genetic variation in a given sample. Furthermore, the *MAG* gene variants may help parse out molecular subtypes of schizophrenia that could have important implications for treatment decisions in the future. Overall, our findings highlight the importance of *MAG* gene variation in brain morphometry in schizophrenia.
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